InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
InterCure Ltd.NASDAQ: INCR
EBITDA · Q2 FY2025 · quarter ended Jun 2025
EBITDA declines year over year
Q2 FY2025 EBITDA of ₪7.13M fell 1.1% year over year, ahead of the -1677.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 0.0% from the prior quarter.
Context
- EBITDA amounted to 2.7% of revenue in FY2025, down 18.8 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether next quarter's EBITDA reaches the consensus estimate of ₪181.47K, a +100.4% change from the same quarter last year.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2025
- ₪7.13M+0.0% QoQ
- Last fiscal yearDec 2025
- -₪7.29M+85.8% YoY
- LTMJun 2025
- -₪79.49M-1677.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.1% | +100.4% | +101.5 pp |
| 1 year | +85.8% | — | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
ILS · from the income statement
- Latest · FY2025
- (7.29M) ILS
- Year-over-year change
- +85.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.29M) | +85.8% |
| FY2024 | 2024-12-31 | (51.31M) | -114.7% |
| FY2023 | 2023-12-31 | (23.9M) | -134.0% |
| FY2022 | 2022-12-31 | 70.23M | +125.3% |
| FY2021 | 2021-12-31 | 31.17M | — |
EBITDA vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1677.7% is the lowest of 9, against a peer median of +27.9%.
- EBITDA amounts to 32.7% of revenue for INCR, versus a peer median of 59.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M USD | +264.5% | — | 223.7% | |
| LTM Mar 2026 | -$5.79M USD | -288.4% | -67.3% | 5.7% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -CA$10.88M CAD | +76.6% | — | 59.3% |
| LTM Mar 2026 | -CA$36.27M CAD | -16.2% | — | — | |
| LTM Mar 2026 | -$39.25M USD | -164.0% | — | — | |
| LTM Mar 2026 | -$46.12M USD | +63.6% | — | — | |
| LTM Mar 2026 | -$52.24M USD | -1.2% | — | 1327.8% | |
| LTM Mar 2026 | -$53.01M USD | +56.9% | — | 22.3% | |
| LTM Jun 2025 | -₪79.49M ILS | -1677.7% | — | 32.7% | |
| Peer median (excluding INCR) | — | +27.9% | -67.3% | 59.3% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.68M | 388.68M | 355.55M | 238.85M | 270.2M |
| Cost of Revenue | 128.55M | 233.6M | 250.46M | 208.61M | 237.02M |
| Gross Profit | 91.13M | 155.08M | 105.1M | 30.23M | 33.18M |
| Gross Margin | 41.5% | 39.9% | 29.6% | 12.7% | 12.3% |
| Research & Development | 1.24M | 632K | 388K | 414K | 390K |
| Selling, General & Admin | 53.46M | 97.32M | 86.24M | 84.63M | 80.41M |
| Operating Expenses | 62.95M | 104.46M | 146.66M | 97.44M | 26.45M |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| EBITDA | 31.17M | 70.23M | (23.9M) | (51.31M) | (7.29M) |
| EBITDA Margin | 14.2% | 18.1% | -6.7% | -21.5% | -2.7% |
| Operating Income | 28.19M | 50.63M | (41.57M) | (67.21M) | 6.73M |
| Operating Margin | 12.8% | 13.0% | -11.7% | -28.1% | 2.5% |
| Interest Income | 130K | 844K | 4.55M | 2.7M | 1.56M |
| Interest Expense | 5.05M | 14.69M | 24.22M | 20.65M | 19.66M |
| Other Income / Expenses | (9.45M) | (6.79M) | (19.72M) | (20.12M) | (50.84M) |
| Income Before Tax | 18.74M | 43.84M | (61.29M) | (87.32M) | (44.1M) |
| Pre-Tax Margin | 8.5% | 11.3% | -17.2% | -36.6% | -16.3% |
| Income Tax Expense | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Net Income | 4.69M | 44.82M | (61.96M) | (67.8M) | (35.71M) |
| Net Margin | 2.1% | 11.5% | -17.4% | -28.4% | -13.2% |
| EPS (Basic) | 0.12 | 0.99 | (1.36) | (1.42) | (0.63) |
| EPS (Diluted) | 0.11 | 0.99 | (1.36) | (1.42) | (0.63) |
| Weighted Avg Shares | 38.49M | 45.35M | 45.56M | 47.77M | 56.8M |
| Weighted Avg Shares (Diluted) | 40.84M | 45.35M | 45.57M | 47.77M | 56.8M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.